In phase 2 study of INO-5401 in combination with cemiplimab, Inovio Pharmaceuticals Inc (NASDAQ:INO) achieved success in ensuring the progression-free survival of patients who are diagnosed with GBM (glioblastoma multiforme). The phase 2 study is conducted using INO 9012, and INO 5401 in combination with a PD-1 blocking antibody – Libtayo on fifty-two patients diagnosed […]
Inovio Pharmaceuticals Inc
Recent Posts
Popular Post
-
InnerScope Hearing Technologies (OTC: INND) Launches HearingAssist Brand of FDA-Registered OTC Rechargeable Hearing Aids on Target.com
-
Sports Gambling and the Horse Racing Market
-
ZICIX+CTIP-FII RECEIVES NOTICE TO PROCEED FROM PROJECT OWNER TO START THE $20 MILLION SENIOR CITIZENS RESIDENCE PROJECT IN NEWARK, NEW JERSEY
-
Principal Solar to Acquire Minerva-Rockdale Leases, Wells, and Assets
-
Kona Gold Beverage, Inc Announces its Ooh La Lemin Lemonades to be sold in Town Pump Convenience Stores in Montana
